<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055704</url>
  </required_header>
  <id_info>
    <org_study_id>09-002996</org_study_id>
    <nct_id>NCT01055704</nct_id>
  </id_info>
  <brief_title>Effect of Methylnaltrexone on GI Transit in Healthy Volunteers</brief_title>
  <official_title>Effect of Methylnaltrexone on Gastrointestinal and Colonic Transit in Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double blind, placebo-controlled study evaluating the
      effects of placebo, codeine, methylnaltrexone and codeine with methylnaltrexone on
      gastrointestinal motility and colonic transit of solids in healthy human subjects.

      The hypotheses are:

        1. Methylnaltrexone administered subcutaneously enhances gastrointestinal motility with
           acceleration of overall colonic transit, and ascending colon emptying of solids in
           healthy humans.

        2. Methylnaltrexone significantly accelerates colonic transit that is delayed by codeine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology

      Following the initial screening visit (visit 1), participants will be randomized to study
      medication, either 0.30mg/kg methylnaltrexone subcutaneously or placebo once daily and 30 mg
      codeine orally or placebo taken four times daily for a total of five days. Participants will
      be randomly assigned to study medication and allocation will be concealed. A urine pregnancy
      test will be performed for all females of child bearing potential within the 48 hours prior
      to the receipt of study medication. Note that females who are status post bilateral tubal
      ligation, hysterectomy or postmenopausal are exempted from this test. Study medication will
      be administered on study med days 1, 2 and 3 (visits 2, 3 and 4) at the Clinical Research
      Unit (CRU). Participants will return for scintigraphic assessment of gastric, small bowel and
      colonic transit of solids on study med days 4 and 5 (visits 5 and 6). The transit studies
      will be undertaken on over a 48 hour time period; no study medication is given on the final
      day of transit (visit 7).

      Investigational product, dosage, mode of administration, duration of treatment

      0.30 mg/kg methylnaltrexone or placebo subcutaneously once daily and 30 mg codeine or placebo
      orally four times daily for five consecutive days.

      Treatment groups

        1. placebo + placebo (8 participants)

        2. placebo + codeine 120mg (8 participants)

        3. methylnaltrexone 0.30 mg/kg + placebo (16 participants)

        4. methylnaltrexone 0.30 mg/kg + codeine 120 mg (16 participants)

      Efficacy assessments

        1. Scintigraphic gastrointestinal and colonic transit

        2. Assessment of bowel pattern frequency and consistency made by the patient using the
           bowel pattern diary

      Safety assessments

      No safety assessments (routine laboratory analysis, ECG etc) will be performed as both
      methylnaltrexone and codeine are FDA approved medications

      Statistical analysis

      The overall effects of the methylnaltrexone treatment on the primary and secondary response
      measures will be assessed using an analysis of covariance (ANCOVA) with suitable
      transformation for skewness in the distributions of measured responses if necessary (e.g.,
      ANCOVA on ranks or an arcsine square root transformation for the proportion of marker in the
      colon at 6 hours). The covariates considered for inclusion in the analyses will be age,
      gender and body mass index. An a priori anticipated contrast (overall drug vs. placebo) will
      be examined (α = 0.05). The specific comparisons of methylnaltrexone vs placebo and codeine
      vs codeine plus methylnaltrexone are of significant interest, and since they are related to
      specific hypotheses, no change in α from 0.05 is planned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Geometric Center at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Ascending Colon Emptying</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Gastric Emptying of Solid</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Geometric Center at 4 Hours</measure>
    <time_frame>4 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Geometric Center at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Filling at 6 Hours</measure>
    <time_frame>6 hours</time_frame>
    <description>Percent of solids reaching the colon at 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>daily</time_frame>
    <description>Stool frequency was self reported in a daily bowel pattern diary for 13 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency as Reported From the Bristol Stool Scale</measure>
    <time_frame>Daily</time_frame>
    <description>Bristol Stool Scale a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation, with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Gastric Motility Disorder</condition>
  <arm_group>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Codeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylnaltrexone + codeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone only</intervention_name>
    <description>0.30 mg/kg subcutaneous injection daily</description>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <other_name>MNTX</other_name>
    <other_name>Relistor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Codeine only</intervention_name>
    <description>30 mg taken orally four times daily for 5 days</description>
    <arm_group_label>Codeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone + codeine</intervention_name>
    <description>Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days</description>
    <arm_group_label>Methylnaltrexone + codeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + placebo</intervention_name>
    <description>Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Males and non-pregnant, non-breastfeeding females

          -  18-65 years old

          -  No functional GI disorders on the short Bowel Disease Questionnaire (BDQ)

          -  A BMI greater than 22.0

        Exclusion criteria

          -  Structural or metabolic diseases/conditions that affect the gastrointestinal system or
             functional gastrointestinal disorders. The short version of the Bowel Disease
             Questionnaire (BDQ) will be exclude functional GI disorders. More than three positive
             responses will exclude participation.

          -  Unable to withdraw from the following medications 48 hours prior to study entry:Any
             medication that alters GI transit including but not limited to laxatives, magnesium or
             aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics,
             tricyclic antidepressants, SSRI and newer antidepressants; analgesic drugs including
             opiates, NSAID, COX 2 inhibitors (note : Tylenol is permitted); GABAergic agents and
             benzodiazepines. Note: Concomitant medications will be reviewed on a case by case
             basis by the study physicians.

          -  Subjects who are considered by the investigator to be alcoholics not in remission or
             known substance abusers. Alcohol must be avoided from seven days prior to beginning
             the study medication until the completion of the study.

          -  Subjects who have participated in another clinical study within the past 30 days.

          -  Clinical evidence (including physical exam and review of the medical history) of
             significant cardiovascular, respiratory, renal, hepatic, pulmonary, gastrointestinal,
             hematological, neurological, psychiatric, or other disease that interfere with the
             objectives of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Wong BS, Rao AS, Camilleri M, Manabe N, McKinzie S, Busciglio I, Burton DD, Ryks M, Zinsmeister AR. The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment Pharmacol Ther. 2010 Oct;32(7):884-93.</citation>
    <PMID>20839388</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <results_first_submitted>July 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2011</results_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <name_title>Michael Camilleri, MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Methylnaltrexone</keyword>
  <keyword>Codeine</keyword>
  <keyword>Gastrointestinal motility</keyword>
  <keyword>Colonic transit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Codeine</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants included males and non-pregnant, non-breastfeeding females aged 18 to 55 years. All subjects had a minimum body mass index (BMI) of 22 kg/m2.</recruitment_details>
      <pre_assignment_details>Subjects were screened for eligibility within 28 days of Day 1 of the study. They were stratified based on gender and BMI (&lt;25, ≥25 kg/m2) and randomized into one of four treatment groups: Treatment groups were randomly assigned in fixed block sizes according to a schedule provided by the study statistician (ARZ). Allocation sequence was concealed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methylnaltrexone 0.30 mg/kg</title>
        </group>
        <group group_id="P2">
          <title>Codeine 30 mg</title>
        </group>
        <group group_id="P3">
          <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methylnaltrexone 0.30 mg/kg</title>
        </group>
        <group group_id="B2">
          <title>Codeine 30 mg</title>
        </group>
        <group group_id="B3">
          <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" spread="2.6"/>
                    <measurement group_id="B2" value="39.4" spread="3.8"/>
                    <measurement group_id="B3" value="31.6" spread="2.7"/>
                    <measurement group_id="B4" value="36.1" spread="3.6"/>
                    <measurement group_id="B5" value="37.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colonic Geometric Center at 24 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Colonic Geometric Center at 24 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.2"/>
                    <measurement group_id="O3" value="1.9" spread="0.3"/>
                    <measurement group_id="O4" value="2.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.902</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.389</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.835</ci_lower_limit>
            <ci_upper_limit>0.739</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.709</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.351</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.578</ci_lower_limit>
            <ci_upper_limit>0.841</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 of Ascending Colon Emptying</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Ascending Colon Emptying</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="2.2"/>
                    <measurement group_id="O2" value="24.0" spread="3.9"/>
                    <measurement group_id="O3" value="23.6" spread="3.3"/>
                    <measurement group_id="O4" value="14.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.971</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.669</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.415</ci_lower_limit>
            <ci_upper_limit>7.472</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.591</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.280</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.208</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.792</ci_lower_limit>
            <ci_upper_limit>6.233</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 of Gastric Emptying of Solid</title>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Gastric Emptying of Solid</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.7" spread="5.1"/>
                    <measurement group_id="O2" value="104.0" spread="14.1"/>
                    <measurement group_id="O3" value="126.8" spread="11.9"/>
                    <measurement group_id="O4" value="101.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-34.425</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.670</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.097</ci_lower_limit>
            <ci_upper_limit>-4.753</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.989</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.181</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.240</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.962</ci_lower_limit>
            <ci_upper_limit>26.598</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Geometric Center at 4 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Colonic Geometric Center at 4 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.236" spread="0.105"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.379" spread="0.130"/>
                    <measurement group_id="O4" value="0.347" spread="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.401</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.211</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.827</ci_lower_limit>
            <ci_upper_limit>0.025</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.610</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.287</ci_lower_limit>
            <ci_upper_limit>0.482</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Geometric Center at 48 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Colonic Geometric Center at 48 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit. A GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.3"/>
                    <measurement group_id="O2" value="3.3" spread="0.4"/>
                    <measurement group_id="O3" value="2.8" spread="0.3"/>
                    <measurement group_id="O4" value="4.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.728</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.497</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.278</ci_lower_limit>
            <ci_upper_limit>1.734</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.448</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.795</ci_lower_limit>
            <ci_upper_limit>1.017</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Filling at 6 Hours</title>
        <description>Percent of solids reaching the colon at 6 hours</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Colonic Filling at 6 Hours</title>
          <description>Percent of solids reaching the colon at 6 hours</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="5.7"/>
                    <measurement group_id="O2" value="23.7" spread="11.2"/>
                    <measurement group_id="O3" value="28.0" spread="6.9"/>
                    <measurement group_id="O4" value="34.5" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI as covariates</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.889</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.772</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.583</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.678</ci_lower_limit>
            <ci_upper_limit>27.223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.274</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.607</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.356</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.362</ci_lower_limit>
            <ci_upper_limit>35.577</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency</title>
        <description>Stool frequency was self reported in a daily bowel pattern diary for 13 days.</description>
        <time_frame>daily</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>Stool frequency was self reported in a daily bowel pattern diary for 13 days.</description>
          <units>Stools</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.1"/>
                    <measurement group_id="O2" value="0.63" spread="0.2"/>
                    <measurement group_id="O3" value="0.7" spread="0.1"/>
                    <measurement group_id="O4" value="1.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.214</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.178</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.572</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.412</ci_lower_limit>
            <ci_upper_limit>0.357</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency as Reported From the Bristol Stool Scale</title>
        <description>Bristol Stool Scale a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation, with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5–7 tending towards diarrhea.</description>
        <time_frame>Daily</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylnaltrexone 0.30 mg/kg</title>
          </group>
          <group group_id="O2">
            <title>Codeine 30 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency as Reported From the Bristol Stool Scale</title>
          <description>Bristol Stool Scale a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation, with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5–7 tending towards diarrhea.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.3"/>
                    <measurement group_id="O2" value="3.1" spread="0.5"/>
                    <measurement group_id="O3" value="3.3" spread="0.3"/>
                    <measurement group_id="O4" value="3.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.497</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.374</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.255</ci_lower_limit>
            <ci_upper_limit>0.261</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed using analysis of covariance (ANCOVA) with gender and/or BMI included as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <method>ANCOVA</method>
            <method_desc>Error degrees of freedom adjusted for number of missing values imputed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.342</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.756</ci_lower_limit>
            <ci_upper_limit>0.630</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methylnaltrexone 0.30 mg/kg</title>
        </group>
        <group group_id="E2">
          <title>Codeine 30 mg</title>
        </group>
        <group group_id="E3">
          <title>Methylnaltrexone 0.30 mg/kg + Codeine 30 mg</title>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn or sting with injection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not evaluate dose-response. A higher dosage of MNTX may be needed to produce a detectable effect on GI and colonic transit as well as bowel pattern in healthy subjects who are naive to opioid agonists during MNTX initiation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Michael Camilleri</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>5072662305</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

